VBIO

distress 9/10 · high distress / dilution risk

$0.27-6%today-94% from 52w high

valionbio.com52 employeesFounded 2016San Antonio, TXBiotechnology

Revenue

pre-revenue

Liquidity

$7M

Runway

0.7 yrs

Shares 1y

+196%

Price & events

-79.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-6.1%

-45.2%

-49.8%

-76.1%

-78.6%

-93.8%

-94.9%

—

-100.0%

All

Overview

Market Cap: $856.54K
Volume: 214.40K
52 Week Range: $0.27 – $4.38
Total Shares: 3.20M
Float Shares: 2.56M
Short %: 4.91%
% Held by Insiders: 1.98%
% Held by Institutions: 14.77%
RVOL: 0.36x
Beta: 1.83

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

2025-05-09partnershipEntolimod · GMP manufacturing validation agreement with Scorpius BioManufacturing for acute radiation syndrome (ARS)SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 3,200,824 · 10 offerings/1y · 3 PIPEs

2026-07-17S-1shelf_registration
2026-06-188-Kprivate_placement
2026-04-15EFFECTshelf_effective
2026-04-15424B3offering
2026-04-13S-1shelf_registration
2026-03-138-Kmaterial_agreement
2026-02-098-Kprivate_placement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified